PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
10.76%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
11.35%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
31.03%
EPS growth of 31.03% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
31.72%
Diluted EPS growth of 31.72% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
29.31%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
29.44%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth of 2.31% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
3.06%
FCF growth of 3.06% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
64.50%
OCF/share CAGR of 64.50% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
73.57%
3Y OCF/share growth of 73.57% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-9976.84%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-124.34%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
76.73%
3Y net income/share CAGR of 76.73% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1493.31%
Equity/share CAGR of 1493.31% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-38.28%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-74.77%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth of 78.33% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
127.26%
BV/share growth of 127.26% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-9.95%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-7.53%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-21.01%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.